Current Effective Therapeutics in Management of COVID-19
The current pandemic due to the SARS-CoV-2 virus has caused irreparable damage globally. High importance is placed on defining current therapeutics for Coronavirus Disease 2019 (COVID-19). In this review, we discuss the evidence from pivotal trials that led to the approval of effective therapeutics in the treatment and prevention of COVID-19. We categorize them as effective outpatient and inpatient management strategies The review also attempts to contextualize the efficacy of therapeutics to the emerging variants. Vaccines, which remain the most effective prevention against hospitalization and deaths is not included in this review..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of Clinical Medicine - 11(2022), 13, p 3838 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kavya Atluri [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| doi: |
10.3390/jcm11133838 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ02908850X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ02908850X | ||
| 003 | DE-627 | ||
| 005 | 20240414073432.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm11133838 |2 doi | |
| 035 | |a (DE-627)DOAJ02908850X | ||
| 035 | |a (DE-599)DOAJa94279bc2ae848369a271aad01355cbc | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Kavya Atluri |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current Effective Therapeutics in Management of COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The current pandemic due to the SARS-CoV-2 virus has caused irreparable damage globally. High importance is placed on defining current therapeutics for Coronavirus Disease 2019 (COVID-19). In this review, we discuss the evidence from pivotal trials that led to the approval of effective therapeutics in the treatment and prevention of COVID-19. We categorize them as effective outpatient and inpatient management strategies The review also attempts to contextualize the efficacy of therapeutics to the emerging variants. Vaccines, which remain the most effective prevention against hospitalization and deaths is not included in this review. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a therapeutics | |
| 650 | 4 | |a omicron | |
| 650 | 4 | |a coronavirus disease 2019 | |
| 650 | 4 | |a monoclonal antibodies | |
| 650 | 4 | |a Casirivimab plus imdevimab | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Iris Aimlin |e verfasserin |4 aut | |
| 700 | 0 | |a Shitij Arora |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Clinical Medicine |d MDPI AG, 2013 |g 11(2022), 13, p 3838 |w (DE-627)DOAJ000006793 |x 20770383 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:13, p 3838 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/jcm11133838 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/a94279bc2ae848369a271aad01355cbc |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2077-0383/11/13/3838 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2077-0383 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 13, p 3838 | ||